|
CA2542303A1
|
|
A composition and method of treatment for urogenital conditions
|
|
US7135548B2
|
|
Modified α-MSH peptides and derivatives thereof
|
|
US2004219232A1
|
|
Methods and compounds for treating malabsorption diseases and inflammatory conditions of the gastrointestinal tract
|
|
AU2003290886A8
|
|
Modified alpha-msh peptides and derivatives thereof
|
|
AU2003291524A1
|
|
Treatment of ophthalmic conditions with kpv and kpv dimers
|
|
AU2003249173A1
|
|
Alpha-melanocyte stimulating hormone peptides protection in organ transplantation
|
|
US7244710B2
|
|
Treatment of ophthalmic infections using antimicrobial peptides
|
|
EP1432432A2
|
|
A cancer treatment system
|
|
US6939846B2
|
|
Use of a polypeptide for treatment of pruritis in animals
|
|
US7115574B2
|
|
System and method for support legacy operating system booting in a legacy-free system
|
|
WO02069884A2
|
|
A sunburn treatment and sunburn prevention method
|
|
US2002137685A1
|
|
Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
|
|
AU5929501A
|
|
Method and composition for rapid delivery of bioactive compounds to the systemiccirculation via the nasal membrane
|
|
AU6296001A
|
|
New antibodies to biological membranes
|
|
AU5742001A
|
|
A gene therapy system and method using alpha-msh and its derivatives
|
|
US6894028B2
|
|
Use of KPV tripeptide for dermatological disorders
|
|
US2002146374A1
|
|
Compounds for treating fungal pathologies of the oral cavity
|
|
US6800291B1
|
|
Uro-genital condition treatment system
|
|
US6803044B1
|
|
Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus
|
|
WO0059527A1
|
|
Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
|
